SCYNEXIS Reports Positive Phase 1 Safety for SCY-770, Phase 2 to Start Q4 2026

SCYNEXIS announced that SCY-770 was well tolerated in a Phase 1 study in healthy adults, supporting dose selection. A Phase 2 proof-of-concept trial in ADPKD is on track to initiate in Q4 2026.